Myriad Genetics has entered into expanded, non-exclusive global pharma deals with AstraZeneca to provide companion diagnostics for the olaparib Phase 3 clinical development program.
Olaparib is an investigational orally active poly-ADP ribose polymerase inhibitor being developed by AstraZeneca for the treatment of various tumor types including BRCA-mutated breast and ovarian cancers.
Under the expanded pharma deals, Myriad will build out a new laboratory within its Salt Lake City facility in accordance with U.S. Food and Drug Administration regulations for companion diagnostic devices.
In August, the FDA approved the Investigational Device Exemption for BRACAnalysis filed by Myriad, enabling clinical studies with olaparib to include BRACAnalysis testing as a companion diagnostic.
The pharma deals build on existing pharma deals through which Myriad provided supply of BRACAnalysis to support the Phase 2 development program for olaparib in breast and ovarian cancers.
Specific terms of the pharma deals were not disclosed.
Report: Partnering Deals and Alliances with AstraZeneca
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity